On Sept. 3, 2020, Sanofi and GSK announced the start of the Phase 1/2 clinical trial for their adjuvanted COVID-19 vaccine. The vaccine candidate, developed in partnership by Sanofi and GSK, uses the same recombinant protein-based technology as one of Sanofiﾒs seasonal influenza vaccines with GSKﾒs established pandemic adjuvant technology.